Finally, the Hub gene was imported into the DGIbd database to obtain 11 FDA-approved drugs, which were further screened through a literature search to find five potential drugs capable of treating AS and NASH, namely, calcitonin, anhydrous tacrolimus, tretinoin, chondroitin sulfates, and zoledronic acid anhydrous. Here, ELAVL2 is linked to metabolic dysfunction-associated steatohepatitis.